<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26635">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759991</url>
  </required_header>
  <id_info>
    <org_study_id>61067</org_study_id>
    <nct_id>NCT02759991</nct_id>
  </id_info>
  <brief_title>Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.</brief_title>
  <official_title>An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian Institute of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the effectiveness of hepatitis E virus vaccine given in
      women of child bearing age in preventing HEV disease during pregnancy among women in rural
      Bangladesh.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of HEV vaccine in preventing HEV diseases among women in Bangladesh</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the effectiveness of hepatitis E virus (HEV) vaccine in preventing HEV disease during pregnancy among women in rural Bangladesh</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events related to vaccination as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the safety and immunogenicity of HEV vaccine in Bangladeshi women of childbearing age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of HEV vaccine in preventing HEV disease in non-pregnant Bangladeshi women of childbearing age</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate serological correlates of protection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20745</enrollment>
  <condition>Hepatitis E Infection</condition>
  <arm_group>
    <arm_group_label>HEV vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hecolin, 0.5 ml intramuscular injection day 0, 1 month and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hecolin</intervention_name>
    <description>0.5ml Hecolin vaccine im. on day 0, 1 month and 6 months.</description>
    <arm_group_label>HEV vaccine</arm_group_label>
    <other_name>HEV 239</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepa-B</intervention_name>
    <description>1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.</description>
    <arm_group_label>HBV vaccine</arm_group_label>
    <other_name>Hepatitis B virus (HBV) vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 16-39 years

          -  Living in Matlab area

        Exclusion Criteria:

          -  Pregnancy

          -  Allergic to vaccine components

          -  Serious chronic diseases

          -  Acute illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Dudman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian Institute of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K Zaman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Child and Adolescent Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>K Zaman, PhD</last_name>
    <phone>880 1713047100</phone>
    <email>kzaman@icddrb.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>International Centre for Diarrhoeal Disease Research, Bangladesh</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K Zaman, PhD</last_name>
      <phone>880 1713047100</phone>
      <email>kzaman@icddrb.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 29, 2016</lastchanged_date>
  <firstreceived_date>March 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis E virus</keyword>
  <keyword>Viral Hepatitis Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis E</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
